Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Bath & Body Works Inc (BBWI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Bath & Body Works Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.9 (market cap $4.49B), while Bath & Body Works Inc trades at $19.44 (market cap $4.16B). The key difference: ACADIA Pharmaceuticals Inc. and Bath & Body Works Inc are close in size by market cap, and Bath & Body Works Inc pays a 3.88% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | BBWI | |
|---|---|---|
Market Cap | $4.49B | $4.16B |
Sector | Health | Consumer Cyclical |
52-Week High | $28.06 | $33.65 |
52-Week Low | $20.06 | $14.85 |
Enterprise Value | $3.69B | $8.05B |
Dividend Yield | — | 3.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
BBWI trades at $20.62, down 6.1% over 24 hours, with a bullish technical signal from moving averages and neutral oscillators. The stock is valued attractively with a P/E of 6.23 and P/S of 0.62, while recent earnings beat expectations in Q1 2026. Revenue has declined over five years, but the company maintains strong cash flow and a new partnership with Ulta Beauty aims to expand reach.
The outlook is mixed: deep valuation discounts and strategic initiatives like the Ulta partnership offer upside, but persistent revenue declines and high debt pose risks. Analyst consensus is a $22.50 price target with no sell ratings, indicating cautious optimism for a turnaround if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Bath & Body Works Inc
Bath & Body Works is a specialty home fragrance and fragrant body care retailer operating under the Bath & Body Works, C.O. Bigelow, and White Barn brands. The company generates most of its business in North America, with less than 5% of sales from international markets in fiscal 2021. For fiscal 2021, 72% of sales stemmed from the brick-and-mortar network (which is composed of more than 1,700 retail stores), up from 65% in 2020, as consumer shopping patterns began to return to normal. Future growth is expected from store reformatting, digital and international channels, as well as new category expansion.
Read more on BBWI →
